The role of hypoxia-inducible factors in tumorigenesis

Cell Death and Differentiation

Volumn 15, Issue 4, 2008, Pages 678-685

  Rankin, E B ^a   Giaccia, A J ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL FACTOR; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1BETA; HYPOXIA INDUCIBLE FACTOR 2; HYPOXIA INDUCIBLE FACTOR 2ALPHA; HYPOXIA INDUCIBLE FACTOR 3ALPHA; OXYGEN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL METABOLISM; CELL PROLIFERATION; ERYTHROPOIESIS; GENE EXPRESSION REGULATION; GLUCOSE TRANSPORT; HUMAN; HYPOXIA; METASTASIS; NONHUMAN; OXYGEN TRANSPORT; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; TUMOR VASCULARIZATION;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; ANOXIA; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL DIFFERENTIATION; CELL HYPOXIA; CELL PROLIFERATION; ENERGY METABOLISM; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OXYGEN; SIGNAL TRANSDUCTION;

EID: 40949142209     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2008.21     Document Type: Review

References (104)

1. Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr Open Cell Biol 2001; 13: 167-171.
2. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995; 270: 1230-1237.
3. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998; 95 7987-7992.
4. Pugh CW, O'Rourke JF, Nagao M, Gleadle JM, Ratcliffe PJ. Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit. J Biol Chem 1997; 272: 11205-11214.
5. Wenger RH, Rolfs A, Marti HH, Guenet JL, Gassmann M. Nucleotide sequence, chromosomal assignment and mRNA expression of mouse hypoxia-inducible factor-1 alpha. Biochem Biophys Res Commun 1996; 223:54-59.
6. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcripdon factor selectively expressed in endothelial cells. Genes Dev 1997; 11: 72-82.
7. Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 1997; 94: 4273-4278.
8. Flamme I, Fröhlich T, von Reutern M, Kappel A, Damert A, Risau W. HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 alpha and developmentally expressed in blood vessels. Mech Dev 1997; 63 51-60.
9. Hu CJ, Sataur A, Wang L, Chen H, Simon MC. The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha. Mol Biol Cell 2007; 18: 4528-4542.
10. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 2003; 23: 9361-9374.
11. Wiesener MS, Jürgensen JS, Rosenberger C, Scholzze CK, Hörstrup JH, Warnecke C et al. Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J 2003; 17: 271-273.
12. Gu YZ, Moran SM, Hogenesch JB, Wartman L, Bradfield CA. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducilbe factor subunit HIF3alpha. Gene Expr 1998; 7 205-213.
13. Makino Y, Cao R, Svensson K. Bertilsson G, Asman M, Tanaka H et al Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001; 414: 550-554.
14. Reyes H, Reisz-Porszasz S, Hankinson O. Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science 1992; 256: 1193-1195.
15. Hoffman EC, Reyes H, Chu FF, Sander F, Conley LH, Brooks BA et al. Cloning of a factor required for activity of the Ah (dioxin) receptor. Science 1991; 252: 954-958.
16. Whitelaw ML, Gustafsson JA, Poellinger L. Identification of transactivation and repression functions of the dioxin receptor and its basic helix-loop-helix/PAS partner factor Arnt: Inducible versus constitutive modes of regulation. Mol Cell Biol 1994; 14: 8343-8355.
17. Huang LE, Arany Z, Livingston DM, Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 1996; 271: 32253-32259.
18. Hirose K, Morita M, Ema M, Mimura J, Hamada H, Fujii H et al. cDNA doning and tissue-specific expression of a novel basic helix-loop-helix/ PAS factor (Arnt2) with close sequence similarity to the aryll hydrocarbon receptor nuclear translocator (Arnt). Mol Cell Biol 1996; 16: 1706-1713.
19. Maltepe E, Keith B, Arsham AM, Brorson JR, Simon MC. The role of ARNT2 in tumor angiogenesis and the neural response to hypoxia. Biochem Biophys Res Commun 2000; 273: 231-238.
20. 2-regulated prolyl hydroxylation. Science 2001; 292: 468-472.
21. 2 sensing. Science 2001; 292: 464-468.
22. 2 tension. Am J Physiol 1996; 271: C1172-C1180.
23. Mahon PC, Hirota K, Semenza GL. FIH-1: A novel protein that interacts Wth HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 2001; 15: 2675-2686.
24. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw, ML. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 2002; 295: 858-861.
25. Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC, Schumacker PT. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci USA 1998; 95: 11715-11720.
26. Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD et al. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab 2005; 1: 401-408.
27. Mansfield KD, Guzy RD, Pan Y, Young RM, Cash TP, Schumacker PT et al Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation. Cell Metab 2005; 1: 393-399.
28. Brunelle JK, Bell El, Quesada NM, Vercauteren K, Tiranti V, Zeviani M et al. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab 2005; 1: 409-414.
29. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000; 167: 411-421.
30. Osada R, Horiuchi A, Kikuchi N, Yoshida J, Hayashi A, Ota M et al. Expression of hypoxia-inducible factor 1 alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: Nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. Hum Pathol 2007; 38: 1310-1320.
31. Shibaji T, Nagao M, Ikeda N, Kanehiro H, Hisanaga M, Ko S et al. Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer. Anticancer Res 2003; 23: 4721-4727.
32. Winter SC, Shah KA, Han C, Campo L, Turley H, Leek R et al. The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer. Cancer 2006; 107: 757-766.
33. Hui EP, Chan AT, Pazzella F, Turley H, To KF, Poon TC et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngela carcinoma and relationship to survival. Clin Cancer Res 2002; 8 2595-2604.
34. Yoshimura H, Dhar DK, Kohno H, Kubota H, Fujii T, Ueda S et al. Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: Correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin Cancer Res 2004; 10: 8554-8560.
35. Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M et al. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002; 8: 1831-1837.
36. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G et al. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000; 60: 4693-4696.
37. Yang QC, Zeng BF, Dong Y, Shi ZM, Jiang ZM, Huang J. Overexpression of hypoxia-inducible tactor-1\{alpha\} in human osteosarcoma: Correlation with clinicopathological parameters and su. Jpn J Clin Oncol 2007; 37: 127-134.
38. Mizokami K, Kakeji Y, Oda S, Maehara Y. Relationship of hypoxia-inducible factor 1 alpha and p21WAF1/CIP1 expression to cell apoptosis and clinical outcome in patients with gastric cancer. World J Surg Oncol 2006; 4: 94.
39. Bangoura G, Liu ZS, Oan O, Jiang CQ, Yang GF, Jing S. Prognostic significance of HIF-2alpha/EPAS1 expression in hepatocellular carcinoma. World J Gestroenterol 2007; 13: 3176-3182.
40. Theodoropoulos VE, Lazaris ACh, Sofras F, Gerzelis I, Tsoukala V, Ghikonti I et al. Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol 2004; 46: 200-208.
41. Irie N, Matsuo T, Nagate I. Protocol of radiotherapy for glioblastoma according to the expression of HIF-1. Brain Tumor Pathol 2004; 21: 1-6.
42. Giatromanolaki A, Sivridis E, Kouskoukis C, Gatter KC, Harris AL, Koukourakis MI et al. Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res 2003; 13: 493-601.
43. Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K. Pezzella F et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 2001; 85: 881-890.
44. Biju MP, Neumann AK, Bensinger SJ, Johnson RS, Turka LA, Haase VH. Vhlh gone deletion induces Hif-1-mediated cell death in thymocytes. Mol Cell Biol 2004; 24: 9038-9047.
45. Vaupel P, Mayor A. Hypoxia in cancer: Significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26: 225-239.
46. Kim SJ, Rabbani ZN, Dewhirst MW, Vujaskovic Z, Vollmer RT, Schreiber EG et al. Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 2005; 49: 325-335.
47. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis [see comments]. Nature 1999; 399: 271-275.
48. Iliopoulos O, Levy AP, Jiang C, Kaelin Jr WG, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 1996; 93: 10595-10599.
49. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260: 1317-1320.
50. Gnarra JR, Glenn GM, Lalif F, Anglard P, Lerman MI, Zbar B et al. Molecular genetic studies of sporadic and familial renal cell carcinoma. Urol Clin North Am 1993; 20: 207-216.
51. Sprenger SH, Gijtenbeek JM, Wesseling P, Sciot R, van Calenbergh F, Lammens M et al. Characteristic chromosomal aberrations in sporadic cerebellar hemangioblastomas revealed by comparative genomic hybridization. J Neurooncol 2001; 52: 241-247.
52. Mazure NM, Chen EY, Laderoute KR, Giaccia AJ. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinostol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 1997; 90: 3322-3331.
53. Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, Cohen B. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. EMBO J 1998; 17: 5085-5094.
54. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 2001; 112: 363-369.
55. Zundel W, Schindler C, Haas-Kogan D, Koong A, Koper F, Chen E et al Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000; 14: 391-396.
56. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin Jr WG. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003; 4: 147-158.
57. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM et al mTOR inhibition reverses Akt-dopendent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1 -dependent pathways. Nat Med 2004; 10: 594-601.
58. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F et al Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002; 22: 7004-7014.
59. Hanahan D,.Weinberg RA. The hallmarks, of cancer. Cell 2000; 100, 57-70.
60. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
61. Hickey MM, Simon MC. Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. Curr Top Dev Biol 2006; 76: 217-257.
62. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and theraphy. J Clin Oncol 2002; 20: 4368-4380.
63. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and, embryonic vascularization. EMBO J 1998; 17: 3005-3015.
64. Carmeliet P, Dor Y, Herbert A Fukumura D, Brusselmans K, Dewerchin M et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394: 485-490.
65. Chavez JC, Baranova O, Lin J, Pichiule P. The transcriptional activator hypoxia inducible factor 2 (HIF-2/EPAS-1) regulates the oxygen-dependent expression of erythropoietin in cortical astrocytes. J Neurosci 2006; 26: 9471-9481.
66. Raval AR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 2005; 25: 5675-5686.
67. Covello KL, Simon MC, Keith B. Targeted replacement of hypoxia-inducible factor-1alpha by a hypoxia-inducible factor-2alpha knock-in allele promotes tumor growth. Cancer Res 2005; 65: 2277-2286.
68. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
69. Semenza GL. HIF-1 mediates the Warburg effect in dear cell renal carcinoma. J Bioenerg Biomembr 2007; 39: 231-234.
70. Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, Zeller KI et al HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 2007; 11: 407-420.
71. Kondo K, Klco JM, Nakamura E, Lechpammer M, kaelin WG. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002; 1: 237-246.
72. Kondo, K, Kim WY, Lechpammer M, Kaelin Jr WG. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003; 1: E83.
73. Arabi A, Wu S, Ridderstråle K. Bierhoff H, Shiue C, Fatyol K et al c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription. Nat Cell Biol 2005; 7: 303-310.
74. Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 2007; 11: 335-347.
75. Bindra RS, Vasselli JR, Stearman R, Linehan WM, Klausner RD. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res 2002; 62: 3014-3019.
76. Imai T, Horiuchi A, Wang C, Oka K, Ohira S, Nikaido T et al. Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol 2003; 163: 1437-1447.
77. Esteban MA, Tran MG, Harten SK, Hill P, Castellanos MC, Chandra A et al. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res 2006; 66: 3567-3575.
78. Evans AJ, Russell RC, Roche O, Burry TN, Fish JE, Chow VW et al. VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. Mol Cell Biol 2007; 27: 157-169.
79. Erler JT, Bennewith KL, Nicolau M, Dornhöfer N, Kong C, Le QT et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006; 440: 1222-1226.
80. Arya M, Ahmed H, Silhi N, Williamson M, Patel HR. Clinical importance and therapeutic implications of the pivotal CXCL12-CXCR4 (chemokine ligand-receptor) interaction in cancer cell migration. Tumour Biol 2007; 28: 123-131.
81. Phillips RJ, Mestas J, Gharaee-Kermani M, Burdick MD, Sica A, Belperio JA et al. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem 2005; 280: 22473-22481.
82. Zagzag D, Lukyanov Y, Lan L Ali MA, Esencay M, Mendez O. Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 2006; 86: 1221-1232.
83. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003; 425: 307-311.
84. Ceradini DJ, Kulkami AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10 858-864.
85. Reya T, Morrison SJ, Clarke MF, Welssman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
86. Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J et al Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 2005; 9: 617-628.
87. Yun Z, Maecker HL, Johnson RS, Giaccia AJ. Inhibition of PPAR gamma 2 gene expression by the HIF-1-regulated gene DEC1/Stra13: A mechanism for regulation of adipogenesis by hypoxia. Dev Cell 2002; 2: 331-341.
88. Jogi A, Øra I, Nilsson H, Poellinger L, Axelson H, Påhlman S. Hypoxia-induced dedifferentiation in neuroblastoma cells. Cancer Lett 2003; 197: 145-150.
89. Helczynska K, Kronblad A, Jögi A, Nilsson E, Beckman S, Landberg G et al. Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. Cancer Res 2003;63: 1441-1444.
90. Parmar K, Mauch P, Vergillo JA, Sackstein R, Down JD. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA 2007;104: 5431-5436.
91. Lee YM, Jeong CH, Koo SY, Son MJ, Song HS, Bae SK et al. Determination of hypoxic region by hypoxia marker in developing mouse embryos in vivo: A possible signal for vessel development. Dev Dyn 2001; 220: 175-186.
92. 2 tensions and the prevention of differentiation of hES cells. Proc Natl Acad Sci USA 2005; 102 4783-4788.
93. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676.
94. Covello KL, Kehler J, Yu H, Gordan JD, Arsham AM, Hu CJ. HIF-2alpha regulates Oct-4: Effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 2006; 20: 557-570.
95. Acker T, Diez-Juan A, Aragones J, Tjwa M, Brusselmans K, Moons L et al. Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell 2005; 8: 131-141.
96. Mack FA, Rathmell WK, Arsham AM, Gnarra J, Keith B, Simon MC. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell 2003; 3: 75-88.
97. Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE. HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J 2004; 23: 1949-1956.
98. Bruick RK. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci USA 2000; 97: 9082-9087.
99. Sowter HM, Ratcliffe PJ, Watson P, Greenberg AH, Harris AL. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human humors. Cancer Res 2001; 61: 6669-6673.
100. Tracy K, Dibling BC, Spike BT, Knabb JR, Schumacker P, Macleod KF. BNIP3 is an RB/E2F target gone required for hypoxia-induced autophagy. Mol Cell Biol 2007; 27: 6229-6242.
101. Biju MP, Akei Y, Shrimanker N, Haase VH. Protection of HIF-1-deficient primary renal tubular epithelial cells from hypoxia-induced cell death is glucose dependent. Am J Physiol Renal Physiol 2005; 289: F1217-F1226.
102. Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: Role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004; 5: 429-441.
103. Moeller BJ, Dreher MR, Rabbani ZN, Schroeder T, Cao Y, Li CY et al Pleiotropic effects of HIF-1 biockade on tumor radiosensitivity. Cancer Cell 2005; 8: 99-110.
104. Magnon C, Opolon P, Ricard M, Connault E, Ardouin P, Galaup A et al Radiation and inhibition of angiogenesis by canstatin synergize to induce HIF-1alpha-mediated tumor apoptotic switch. J Clin Invest 2007; 117: 1844-1855.